UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 10, 2022

EyePoint Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	**000-51122**	**26-2774444**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(I.R.S. Employer Identification No.)**

480 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices, and Zip Code)

(617) 926-5000
Registrant's Telephone Number, Including Area Code

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.001	**EYPT**	**The Nasdaq Stock Market LLC**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On January 10, 2022, EyePoint Pharmaceuticals, Inc. (the "Company") filed a Current Report on Form 8-K to report that the Company posted an updated corporate presentation on its website at www.eyepointpharma.com. This Amendment No. 1 to Current Report on Form 8-K/A ("Amendment No. 1") is being filed to report that the Company has posted a further updated corporate presentation on its website at www.eyepointpharma.com to correct certain scrivener's errors contained in the previous version of the corporate presentation. A copy of the corrected presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Corporate Presentation, dated January 2022
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYEPOINT PHARMACEUTICALS, INC.

Date: January 12, 2022

By: /s/ George O. Elston
Name: George O. Elston
Title Chief Financial Officer

Exhibit 99.1

Delivering Innovation to the Eye

Investor Presentation
January 2022

EYEPOINT PHARMACEUTICALS

Forward looking statements

Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, including but not limited to statements about our expectations regarding the potential benefits of our partnerships and strategic alliances with other companies, as well as the timing and clinical development of our product candidates, including EYP-1901; the potential for EYP-1901 as a vital, novel twice-yearly treatment for wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion; and our longer term financial and business goals and expectations, are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements are risks and uncertainties inherent in our business including, without limitation: the effectiveness and timeliness of clinical trials, and the usefulness of the data; the timeliness of regulatory approvals; the extent to which COVID-19 impacts our business; our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; our ability to successfully produce sufficient commercial quantities of YUTIQ® and DEXYCU® and to successfully commercialize YUTIQ and DEXYCU in the U.S.; our ability to sustain and enhance an effective commercial infrastructure and enter into and maintain commercial agreements for YUTIQ and DEXYCU; the development of our YUTIQ line extension shorter-duration treatment for non-infectious uveitis affecting the posterior segment of the eye; the success of current and future license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; termination or breach of current license agreements, including our agreements with Ocumension Therapeutics and Equinox Science; our dependence on contract research organizations, co-promotion partners, and other outside vendors and service providers; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; volatility of our stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. We cannot guarantee that the results and other expectations expressed, anticipated or implied in any forward-looking statement will be realized. A variety of factors, including these risks, could cause our actual results and other expectations to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

COMPANY OVERVIEW

Pipeline leveraging proven Durasert® technology *

Compelling pipeline focused on retinal disease

- EYP-1901 - advancing into phase 2 trials for wet AMD, diabetic retinopathy (DR), and retinal vein occlusion (RVO) after positive phase 1 interim results and positive Type C FDA meeting guidance
- Additional molecules and MOAs under evaluation

Durasert® - proven intravitreal (IVT) drug delivery platform

- Sustained local drug delivery
- Constant (zero-order kinetics), stable release of drug in the eye over weeks, months or years
- Safely administered to thousands of patients' eyes across four FDA approved products

Commercial franchises - YUTIQ® and DEXYCU®

- Positioned to break-even in 2022 as stand-alone franchise
- YUTIQ 50 in Phase 3 study supporting an sNDA filing
- DEXYCU sales and marketing now managed by commercial partner ImpriminsRx as we focus on retina

*non-erodible

PLATFORM TECHNOLOGY

DURASERT®

Proven sustained release intravitreal drug delivery



TECHNOLOGY

DURASERT®

Proven safe, sustained intravitreal delivery

- Delivered by a simple, single in-office intravitreal injection
- Continuous, stable release provides consistent and reliable drug delivery over weeks, months, or years

Approved Products

- YUTIQ® (2018, EyePoint) Posterior Segment Uveitis
- ILUVIEN® (2014, Alimera) - DME
- RETISERT® (2005, B&L) - Uveitis
- VITRASERT® (1996, B&L) - CMV retinitis

Development Candidates

- EYP-1901
  - Wet AMD
  - Diabetic Retinopathy (DR)
  - Retinal Vein Occlusion (RVO)
- YUTIQ® 50
  - Posterior Segment Uveitis

Retinal disease focused pipeline

DURASERT PROGRAM	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3
EYP-1901- VOROLANIB (TKI) • Wet AMD • Diabetic retinopathy • Retinal vein occlusion				
YUTIQ® 50 - (FA) • Posterior segment uveitis under sNDA plan				
Evaluating Pre-Clinical Programs				



PIPELINE

EYP-1901 – IVT delivery of vorolanib using bioerodible Durasert® as a potential six-month treatment

Our goal is nothing short of transforming the treatment of wet AMD, diabetic retinopathy, and retinal vein occlusion

PIPELINE

EYP-1901



VOROLANIB | DURASERT

Real World Reality – Even One Missed Injection Can Mean Loss of Vision

AMERICAN ACADEMY OF OPHTHALMOLOGY®

The Effect of Delay in Care among Patients Requiring Intravitreal Injections

Weilin Song, BS,[1] Rishi P. Singh, MD,[2] Aleksandra V. Rachitskaya, MD[3]

- Study evaluated 1,041 pts getting intravitreal anti-VEGF therapies
- 60% went to scheduled follow up - 40% did not
- Conclusion: With frequent injections required for current standard of care, a delay in care of only 5.34 weeks resulted in visual loss
- Sustained release options may give practitioners and patients improved outcomes

EYP-1901 – A Novel Approach to Wet AMD Therapy
Vorolanib in Bioerodible Durasert®



EYP-1901 insert at month 5 post-injection

Bioerodible Durasert® :

Similar technology used in YUTIQ®, Retisert®, and Vitrasert®

- Polyimide shell removed (used for 3-year duration)
- Bioerodible core matrix remains
- Initial burst from the surface of implant
- Constant, zero-order kinetic release rate for months

vorolanib

- Receptor-binding, small molecule tyrosine kinase inhibitor (TKI)
- Activity against all isoforms of VEGF and PDGF
- Oral vorolanib previously studied in a wet AMD ph1 and ph2 programs[1,2]

1. Jackson et al. JAMA Ophthalmol 2017
2. Cohen MN et al. Br J Ophthalmol. 2021

PIPELINE

EYP-1901



VOROLANIB | DURASERT

Effective blocking of VEGFR Prevents Exudation and Loss of Vision

VEGF SIGNALING PATHWAYS



EYP-1901 – Intellectual Property Overview



- USFDA Exclusivity
  - Potential 5 years for new chemical entity or 3 years for new clinical investigation
- In-Licensed Patents and Applications
  - US patents expiring in 2027
  - US patent expiring in 2037, and related pending US application
  - Ex-US patents and pending patent applications
- EyePoint Patent Applications
  - International Patent Application (PCT) filed in September 2021
  - US provisional application filed in October 2021


EYP-1901 phase 1 trial
interim results

EYP-1901 –DAVIO Phase 1 Study in Wet AMD "Durasert and Vorolanib in Ophthalmology"

6-month interim data summary: All study objectives successfully met

SAFETY

Positive safety data:

- No ocular Serious Adverse Events (SAEs) reported
- No drug-related systemic SAEs reported
- All ocular AEs were ≤ grade 2; the only grade 3 AE was not drug-related

EFFICACY

Positive efficacy Data:

- Stable VA and OCT
- Median time to rescue: 6 months
- Clinically significant reduction in treatment burden

EYP-1901 - DAVIO Phase 1 Study in Wet AMD

Open label, Dose Escalation, No Control Arm

Enrollment

- Previously treated wet AMD eyes only
- No exclusion for presence of fluid

NO mandated EYP 1901 retreatments

Criteria for rescue anti-VEGF therapy*:

- New fluid > 75 microns (OCT) compared to Day-0
- ≥ 2 lines of BCVA secondary to wet AMD compared to Day-0
- New macular hemorrhage secondary to wet AMD

Primary endpoint: safety

- Interim at month-6
- Full readout at month-12

Secondary endpoints:

- BCVA
- CST as measured by OCT



Note: All doses delivered in a single intravitreal injection.
BCVA: best corrected visual acuity; OCT: optical coherence tomography; CST: central subfield thickness

EYP-1901 Phase 1 DAVIO Study Participants and 6-month Follow-Up

Screening Characteristics (N=17) and Follow Up Visits	
Mean age, range (years)	77.4 (67–94)
Female (n, %)	13/17 (76%)
Mean BCVA, range (ETDRS letters)	69 letters, (38-85)
Mean CST, range (microns)	299 microns, (204–441)
Median length of time for wet AMD diagnosis prior to enrollment	17 months
Mean # of injections per year prior to enrollment	8.76 injections/year
Follow Up at 6 months	168 out of 170 (99 %) possible post treatment follow up visits performed

BCVA: best corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy Study; CST: central subfield thickness


EYP-1901 Phase 1 DAVIO Study
6-Month Results: Safety
EyePoint
PHARMACEUTICALS
16 | EYEPOINT
PHARMACEUTICALS

EYP-1901 – Phase 1 DAVIO Study
Primary Endpoint – Safety at 6 months

Positive overall safety data
No ocular serious adverse events (SAEs) reported
No drug-related systemic SAEs reported

No other reported significant adverse events such as:

- No vitreous floaters
- No endophthalmitis
- No retinal detachment
- No implant migration in the anterior chamber
- No retinal vasculitis
- No posterior segment inflammation

Ocular AEs:

- One eye: mild asymptomatic anterior chamber cell/flare; *Treated with Maxitrol® eyedrops – resolved in 8 days –no sequelae or recurrence*
- One eye: asymptomatic vitreous hemorrhage from injection; *Observed*

AC, anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; SAE, serious adverse event

EYP-1901 - Phase 1 DAVIO Study
Summary at 6 Months - Ocular Safety

Treatment Ocular Adverse Events as Occurring by Subject

Event	440 µg (n=3)	1030 µg (n=1)	2060 µg (n=8)	3090 µg (n=5)	Total (N=17)
Ocular SAEs	0	0	0	0	0
Dose-limiting toxicity events	0	0	0	0	0
Vitreous floaters	0	0	0	0	0
Endophthalmitis	0	0	0	0	0
Reduction in BCVA ≥10 letters[a]	1	0	1	1	3
Retinal detachment	0	0	0	0	0
Implant migration into AC	0	0	0	0	0
Ocular inflammation	0	0	1	0	1
Elevated IOP	1	0	0	0	1
Post-treatment ocular pain/discomfort	2	0	1	0	3
Progressive disease activity	1	0	2	8	11
Subconjunctival hemorrhage	0	0	3	1	4
Vitreous haze	0	0	0	0	0
Dry eye syndrome OU	1	0	0	0	1
Worsening cataracts OU	0	0	1	0	1
Worsening meibomian gland dysfunction OU	0	0	1	0	1
Silicone oil bubble	0	0	1	0	1
Lid edema	0	0	1	0	1
Ocular discharge	0	0	1	0	1
Vitreous hemorrhage	0	0	0	1	1
Corneal epitheliopathy secondary to dry eye (OS)	0	0	1	0	1
Flame shaped hemorrhage	1	0	0	0	1
Macular hemorrhage	1	0	0	0	1

AEs of particular interest

a. All mild-to-moderate in severity and determined not related to study drug
b. Grade 1/Mild

AC anterior chamber; AE, adverse event; BCVA, best corrected visual acuity; OS, left eye; OU; both eyes


EYP-1901 Phase 1 DAVIO Study
6 Month Results: visual acuity, CST, rescue free rates, and reduction in treatment burden
EYEPOINT
PHARMACEUTICALS
19 | EYEPOINT
PHARMACEUTICALS

EYP-1901 – Phase 1 DAVIO Study
Average Visual Acuity (VA) Stable 6 Months After Treatment



BCVA: best corrected visual acuity

Interim data – monitored through 6 months

EYP-1901 - Phase 1 DAVIO Study

Central Subfield Thickness (CST) Sustainable Anatomical Control & Efficacy

Average change in CST from screening visit



OCT: optical coherence tomography; CST: central subfield thickness

Interim data – monitored through 6 months

EYP-1901 Phase 1 DAVIO Study

Rescue-free Rates up to Each Visit: Entire Study group



Interim data – monitored through 6 months

EYP-1901 Phase 1 DAVIO Study
Rescue-free Rates up to Each Visit



EYP-1901 Phase 1 DAVIO Study

Details on Patients (n=9) That Received Rescue Anti-VEGF Therapy Up to six months

Cohort	Subject #	Rescue Visit	Reason
Low Dose	2	Month 1	Rescued for CST
Low Dose	3	Month 5	Rescued for CST
Mid Dose	6	Month 5	Rescued for CST
Mid Dose	7	Month 5	Rescued for VA
Mid Dose	10	Month 4	Rescued for CST
Mid Dose	12	Month 3	Rescued for VA
High Dose	13	Month 1	new IRF – did not meet criteria
High Dose	15	Month 1	Rescued for CST
High Dose	17	Month 6	Rescued for CST

CST: central subfield thickness; SRF: subretinal fluid; IRF: intra-retinal fluid

CST's NOT Reading Center Confirmed - Interim data – monitored through 6 months

EYP-1901 Phase 1 DAVIO Study – 6 Month Results

Clinically Significant Reduction in Treatment Burden - *79 % for the entire cohort*



Interim data – monitored through 4 months

EYP-1901 Phase 1 DAVIO Study

Case 1: Entered Dry, Stayed Dry for 9 Months

Low dose cohort (EYP-1901 440 µg)

Screening visits prior to treatment

Initial Diagnosis: *9 months prior to enrollment*



Screening Visit: *6 anti-VEGF injections prior to enrollment*



EYP-1901 Phase 1 DAVIO Study

Case 1: Post-Treatment (No Rescues Through Month 9)

Low dose cohort (EYP-1901 440 µg)



EYP-1901 Phase 1 DAVIO Study

Case 2: Rescued at Month 1 and failure of both SOC and EYP-1901

Low dose cohort (EYP-1901 440 µg)

Prior to Treatment

Screening Visit (9 prior anti-VEGF injections)



EYP-1901 Phase 1 DAVIO Study

Case 2: Rescued at Month 1 and failure of both SOC and EYP-1901

Low Dose Cohort (EYP-1901 440 µg)













Despite early rescue, EYP1901 still reduced treatment burden by 34%

EYP-1901 Phase 1 DAVIO Study

Case 3: Entered the Study With Subretinal Fluid

High dose cohort (EYP-1901 3090 µg)

Prior to treatment

Screening Visit (8 prior anti-VEGF injections)



EYP-1901 Phase 1 DAVIO Study

Case 3: Post-treatment – New Fluid Doesn't Mean Rescue !

High dose cohort (EYP-1901 3090 µg)













EYP-1901 Phase 1 DAVIO Study
6-Month Summary - All Objectives Successfully Met

Proof of Concept for bioerodible Durasert and vorolanib in wet AMD

SAFETY

Positive Safety Data

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs - majority mild and to be expected

EFFICACY

Positive Efficacy Data:

- Stable VA and OCT
- Median time to rescue: 6 months
- **76 %** rescue-free up to 4 months
- **53 %** rescue-free up to 6 months
- Clinically significant reduction in treatment burden by **79 %**

EYP-1901 Phase 1 DAVIO Study
8 month Update For All 17 Patients

SAFETY

Continued Positive Safety Data

- No ocular SAEs reported
- No drug-related systemic SAEs reported
- Ocular AEs - majority mild and to be expected

DURABILITY

7 of 17 (41%) eyes rescue-free through 8-months follow up

EYP-1901 Phase 1 DAVIO Study – January 2022 Update

Clinically Significant Reduction in Treatment Burden - *76 % for the entire cohort*



PIPELINE

EYP-1901



VOROLANIB | DURASERT

Phase 2 Plan

- Positive and collaborative Type C meeting held with FDA in December 2021
  - Obtained guidance on Phase 2 and pivotal studies
- Phase 2 trial in Wet AMD expected to initiate in Q3 of 2022
  - Two doses, randomized and controlled (aflibercept)
  - Approximately 144 patients across the three arms
  - Anticipate leveraging Phase 1 clinical findings and observations around biomarkers to refine Phase 2 clinical trial design
- Phase 2 trial in Diabetic Retinopathy expected to initiate in 2H 2022

EYP-1901 Phase 1 DAVIO Study

Retrospective Sub-Group (N=11) Analysis Based on Entry Criteria and Anticipated Dosing in Phase 2 Wet AMD Study – 88 % reduction in Treatment Burden

Subgroup Analysis of DAVIO Medium and High Dose Patients – Eliminating the 1-month Rescues

SOC Anti-VEGF Injections Before and After Treatment



● Anti-VEGF ○ No rescue injection given □ Missed visit

Reduction in Treatment Burden of 88 % overall

Mid dose (n=8)

-90%

High dose (n=3)

-85%

Interim data – monitored through 6 months

PIPELINE

EYP-1901



VOROLANIB | DURASERT

2022 and Beyond
Positioned to Transform the Ophthalmology Landscape

- Paradigm-shifting potential of DURASERT technology now demonstrated with multiple approved drugs and small molecule agents
  - Ability to utilize technology for small molecule agents with different MOAs
  - Ability to tailor and control dosing frequency for specific indications and patient populations
  - Ability to inject multiple implants with a single injection
- Apply new technological enhancements to DURASERT platform to further expand the scope and scale of new indications



Products

FDA approved commercial products

PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

Approved for the treatment of chronic non-infectious uveitis affecting the back of the eye



- Commercially launched in U.S. in 2019
- Patent protection to August 2027
- Constant and stable release of fluocinolone with Durasert helps prevent uveitis flares for up to 3 years

LICENSE AGREEMENTS

Alimera Sciences, Inc. has rights for non-infectious posterior uveitis in the EMEA

Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension Therapeutics with a royalty on sales payable to EyePoint

PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

Chronic non-infectious uveitis causes blindness with every flare

60K–100K patients are suffering from uveitis in the U.S.

The need

- Flares can cause blindness
- 30,000 Americans become blind each year because of uveitis
- Uveitis lasts a lifetime and often affects people in middle age
- Conventional treatment is burdensome for patients and caregivers

The YUTIQ answer

- 3-year continuous treatment in a single injection that controls flares and preserves eyesight
- Simple administration in the physician's office
- Gives patients and physicians the confidence that comes with three years of assured compliance

PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

Continuous 3-year delivery limits blindness-causing uveitis flares

Time to recurrence of uveitis within 36 months



PRODUCTS

0.18 mg
YUTIQ™
(fluocinolone acetonide intravitreal implant) 0.18 mg

CONTINUOUS CALM IN UVEITIS

Record customer demand* in Q4 2021

*Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors.



PRODUCTS

DEXYCU
(dexamethasone intraocular suspension) 9%

TARGET THE SITE

Treatment of inflammation following ocular surgery



- Effective January 1, 2022 sales and marketing activities to be managed by our commercial alliance partner ImprimisRX
- EyePoint to retain NDA and continue to record revenue and COGS for DEXYCU sales

- DEXYCU eligible for Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022
- Centers for Medicare & Medicaid Services (CMS) extended DEXYCU pass through payment status until December 31, 2022, as part of its Hospital Outpatient Prospective Payment System Final Rule

LICENSE AGREEMENT

Rights for China, Hong Kong, Taiwan, Macau , Korea and certain SE Asia countries licensed to Ocumension Therapeutics with a royalty on sales payable to EyePoint

PRODUCTS

DEXYCU®
(dexamethasone intraocular suspension) 9%

TARGET THE SITE

Record customer demand* in Q4 2021

*Customer demand is defined as units purchased by Surgery Centers or physicians from the specialty distributors.



DELIVERING INNOVATION TO THE EYE

Financial Summary

Solid cash position and growing revenues supporting strong cash runway

- ~$210 million of Cash on December 31, 2021
- $38.9 million of debt on December 31, 2021
- $8.6 million of net product revenues in Q3 2021, a 49% increase over Q3 2020
- $24.1 million of net product revenues YTD September 30, 2021, a 70% increase over YTD September 30, 2020


Delivering Innovation to the Eye
EyePoint
PHARMACEUTICALS